A drug development company developing small molecules and biologics to treat intractable inflammatory conditions and cancer.

Odyssey is an ambitious drug discovery company backed by multiple enabling platform technologies focused on the autoimmune and oncology space. Odyssey has prioritized validated therapeutic targets in large market indications—such as rheumatoid arthritis, Crohn’s disease, lung and colon cancers—but unlike their competition, are pursuing novel drugging strategies that could confer meaningful efficacy or safety benefits. Odyssey’s lead program is entering the clinic in IBD and programs in targeted oncology and arthritis close behind. With a very experienced management team and backing by a top notch syndicate, Odyssey has multiple shots on goal with blockbuster potential and line of sight to the clinic.